Methods for Treating Neuropsychiatric Disorders with NMDA Receptor Antagonists

• US 20100137448A1
• Filed: 07/16/2009
• Published: 06/03/2010
• Est. Priority Date: 12/07/2000
• Status: Abandoned Application

• Current Assignee: Adamas Pharmaceuticals, Inc. (Supernus Pharmaceuticals, Inc.)
• Original Assignee: Adamas Pharmaceuticals, Inc. (Supernus Pharmaceuticals, Inc.)
• Inventors: Lipton, Stuart A., Went, Gregory
• Application Number:
  US12/504,515
• Publication Number:
  US 20100137448A1
• Time in Patent Office: Days
• US Class Current: 514/662
• CPC Class Codes: A61K 31/21 Esters, e.g. nitroglycerine, selenocyanates
• CPC Class Codes: A61P 25/22 Anxiolytics
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

The present invention relates to compositions and methods for treating a human patient afflicted with a neuropsychiatric disorder. Specifically, the invention provides for compositions and methods of modulating or antagonizing the activity of neuronal NMDA receptors, wherein such antagonistic activity is capable of modulating the glutamate induced excitatory response of the neurons, thereby inhibiting an excitotoxic effect, promoting a neurotrophic effect, and thereby providing a therapeutic effect that treats the neuropsychiatric disorder.

Claims

1. A method for treating neuropsychiatric disorders comprising administering to a human patient suffering from a neuropsychiatric disorder, an effective amount of an NMDA receptor antagonist compound to modulate glutamatergic neurotransmission by NMDA receptors in the human patient, thereby treating the neuropsychiatric disorder.

2. The method of claim 1, wherein the neuropsychiatric disorder is major depression.

3. The method of claim 1, wherein the neuropsychiatric disorder is bipolar disorder.

4. The method of claim 1, wherein the neuropsychiatric disorder is anxiety.

5. The method of claim 1, wherein the neuropsychiatric disorder is selected from the group consisting of:

drug addiction, drug dependency, drug withdrawal, and drug tolerance.

6. The method of claim 1, wherein excessive glutamatergic neurotransmission is modulated, thereby mediating an excitotoxic effect of glutamate on neurons.

7. The method of claim 6, wherein mediating the excititoxic effect of glutamate on neurons provides a neuroprotective effect.

8. The method of claim 1, wherein the NMDA receptor antagonist compound modulates NMDA receptor activity in a glutamatergic cortico-striatal or a subthallamicopalladial pathway.

9. The method of claim 8, wherein the NMDA receptor antagonist compound modulates activity in the glutamatergic cortico-striatal or the subthallamicopalladial pathways independent of dopamine or norepinephrine release.

10. The method of claim 1, wherein the NMDA receptor antagonist compound comprises memantine, nitromemantine, its enantiomers, or a pharmaceutically acceptable salt thereof, and the compound is administered to the human patient from a dosage of 0.1 mg/day to 100 mg/day.

11. The method of claim 10, wherein the NMDA receptor antagonist compound is administered to the human patient from a dosage of 5 mg/day to 80 mg/day.

12. The method of claim 10, wherein the NMDA receptor antagonist compound is administered to the human patient from a dosage of 10 mg/day to 35 mg/day.

13. The method of claim 10, wherein the patient suffering from the neuropsychiatric disorder is thereby provided with a therapeutic effect.

14. A method of using a NMDA receptor antagonist compound to modulate glutamatergic neurotransmission in a human patient comprising administering to a patient suffering from a neuropsychiatric disorder, an effective amount of a NMDA receptor antagonist compound to antagonize NMDA receptors in the human patient, thereby modulating glutamatergic neurotransmission by the NMDA receptors and thereby treating the neuropsychiatric disorder.

15. The method of claim 14, wherein the neuropsychiatric disorder is major depression.

16. The method of claim 14, wherein the neuropsychiatric disorder is bipolar disorder.

17. The method of claim 14, wherein the neuropsychiatric disorder is anxiety.

18. The method of claim 14, wherein the neuropsychiatric disorder is selected from the group consisting of:

drug addiction, drug dependency, drug withdrawal, and drug tolerance.

19. The method of claim 14, wherein antagonizing NMDA receptors in the human patient thereby mediates an excitotoxic effect of glutamate on neurons.

20. The method of claim 19, wherein mediating the excititoxic effect of glutamate on neurons provides a neuroprotective effect.

21. The method of claim 14, wherein the NMDA receptor antagonist compound modulates NMDA receptor activity in a glutamatergic cortico-striatal or a subthallamicopalladial pathway.

22. The method of claim 21, wherein the NMDA receptor antagonist compound modulates activity in the glutamatergic cortico-striatal or the subthallamicopalladial pathway independent of dopamine or norepinephrine release.

23. The method of claim 14, wherein the NMDA receptor antagonist compound comprises memantine, nitromemantine, its enantiomers, or a pharmaceutically acceptable salt thereof, and the compound is administered to the human patient from a dosage of 0.1 mg/day to 100 mg/day.

24. The method of claim 14, wherein the NMDA receptor antagonist compound is administered to the human patient from a dosage of 5 mg/day to 80 mg/day.

25. The method of claim 14, wherein the NMDA receptor antagonist compound is administered to the human patient from a dosage of 10 mg/day to 35 mg/day.

26. The method of claim 14, wherein antagonizing NMDA receptors in the human patient thereby provides a therapeutic effect to the human patient suffering from the neuropsychiatric disorder.

27. A method of using a NMDA receptor antagonist compound to modulate glutamatergic neurotransmission in a human patient comprising administering to a patient suffering from a neuropsychiatric disorder, an effective amount of NMDA receptor antagonist compound to antagonize the PCP or MK-801 binding site of NMDA receptors in the human patient, thereby modulating excessive glutamatergic neurotransmission by the NMDA receptors, thereby providing the human patient a neuroprotective effect and a neurotropic effect, and thereby treating the neuropsychiatric disorder.

28. The method of claim 27, wherein the NMDA receptor antagonist compound comprises memantine, nitromemantine, its enantiomers, or a pharmaceutically acceptable salt thereof, and the compound is administered to the human patient from a dosage of 0.1 mg/day to 100 mg/day.

29. The method of claim 27, wherein the NMDA receptor antagonist compound is administered to the human patient from a dosage of 5 mg/day to 80 mg/day.

30. The method of claim 27, wherein the NMDA receptor antagonist compound is administered to the human patient from a dosage of 10 mg/day to 35 mg/day.

31. The method of claim 27, wherein the neuropsychiatric disorder is selected from the group consisting of:

major depressive disorder, bipolar disorder, anxiety, drug addiction, drug dependency, drug withdrawal, and drug tolerance.

32. The use of an NMDA receptor antagonist compound in the manufacture of a medicament to modulate excessive glutamatergic neurotransmission by NMDA receptors for treatment of a human patient suffering from a neuropsychiatric disorder.

33. The use of an NMDA receptor antagonist compound as defined in claim 32 to antagonize the PCP or MK-801 binding site of NMDA receptors in the human patient.

34. The use of an NMDA receptor antagonist compound as defined in claim 33 to modulate excessive glutamatergic neurotransmission by the NMDA receptors, thereby providing the human patient a neuroprotective effect and a neurotropic effect, and thereby treating the neuropsychiatric disorder.

35. The use of an NMDA receptor antagonist compound as defined in claim 32, wherein the medicament provides the human patient with a dosage of the NMDA receptor antagonist compound from 0.1 mg/day to 100 mg/day.

36. The use of an NMDA receptor antagonist compound as defined in claim 32, wherein the medicament provides the human patient with a dosage of the NMDA receptor antagonist compound from 5 mg/day to 80 mg/day.

37. The use of an NMDA receptor antagonist compound as defined in claim 32, wherein the medicament provides the human patient with a dosage of the NMDA receptor antagonist compound from 10 mg/day to 35 mg/day.